Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings From an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother–Infant Pairs During the Transition From Option A to Option B+ in Zimbabwe,Clinical Infectious Diseases

当前位置： X-MOL 学术 › Clin. Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings From an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother–Infant Pairs During the Transition From Option A to Option B+ in Zimbabwe
Clinical Infectious Diseases ( IF 8.2 ) Pub Date : 2017-09-16 , DOI: 10.1093/cid/cix820
Thu-Ha Dinh ₁ , Angela Mushavi ₂ , Ray W Shiraishi ₁ , Beth Tippett Barr ₃ , Shirish Balachandra ₃ , Gerald Shambira ₄ , Justice Nyakura ₄ , Sekesai Zinyowera ₅ , Mufuta Tshimanga ₄ , Owen Mugurungi ₂ , Peter H Kilmarx _{1,

3}

Affiliation

Preventing mother-to-child transmission of human immunodeficiency virus transmission (MTCT) depends on early initiation of antiretroviral therapy (ART). We report the 18-month MTCT risk during the transition from Option A to Option B+ in Zimbabwe, and assess whether ART preconception could eliminate MTCT in breastfeeding populations.

中文翻译：

抗逆转录病毒治疗的时机和出生体重对母婴人类免疫缺陷病毒传播的影响：津巴布韦从选项 A 到选项 B+ 过渡期间的全国代表性母婴对样本的 18 个月前瞻性队列研究结果

预防人类免疫缺陷病毒传播 (MTCT) 的母婴传播取决于早期启动抗逆转录病毒治疗 (ART)。我们报告津巴布韦从选项 A 过渡到选项 B+ 期间的 18 个月 MTCT 风险，并评估 ART 孕前是否可以消除母乳喂养人群的 MTCT。

更新日期：2018-02-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11